Clinical Trials Directory

Trials / Completed

CompletedNCT01190813

Levodopa for the Treatment of Residual Amblyopia

A Randomized Trial of Levodopa as Treatment for Residual Amblyopia (ATS 17)

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
139 (actual)
Sponsor
Jaeb Center for Health Research · Academic / Other
Sex
All
Age
7 Years – 12 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of oral levodopa and patching versus oral placebo and patching as treatment for residual amblyopia in children 7 to \<13 years old with visual acuity of 20/50 to 20/400 in the amblyopic eye.

Detailed description

Amblyopia is the most common cause of monocular visual impairment in both children and young and middle-aged adults. Both patching and atropine are accepted treatment modalities for the management of moderate amblyopia in children. Despite best efforts with conventional amblyopia treatment, many older children and teenagers with amblyopia fail to achieve normal visual acuity in the amblyopic eye. In a previous PEDIG study where children 7 to 12 years old were treated with atropine and patching, only 36% of the children with moderate amblyopia and only 23% of the children with severe amblyopia achieved 20/40 or better acuity. Many clinicians have recognized that conventional therapies with patching and atropine have not been universally successful and have sought alternatives. PEDIG has discussed for several years the problem of residual amblyopia and how the remaining visual acuity deficit could be reduced. A number of research groups have evaluated the short term use of oral levodopa-carbidopa as an adjunct to patching therapy for older children.

Conditions

Interventions

TypeNameDescription
DRUGLevodopa/CarbidopaOral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
DRUGPlaceboOral placebo tid
OTHERPatchingTwo hours of daily patching

Timeline

Start date
2010-09-01
Primary completion
2014-01-01
Completion
2014-04-01
First posted
2010-08-30
Last updated
2016-06-02
Results posted
2015-02-13

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01190813. Inclusion in this directory is not an endorsement.